A silent revolution took place in the field of asthma pathogenesis over the last ten years. Until then, asthma was considered a disease caused mainly by bronchial smooth muscle disfunction (Kay 1991) . Bronchial inflammation has been known as a feature of asthma for decades but it was always associated with terminal stages of the disease, and related to death caused by status asmaticus. Descriptions of severe bronchial infiltration by eosinophils and mononuclear cells, epithelial shedding, luminal plugs formed by exsudated proteins and inflammatory cells were tipically seen as hallmarks of terminal asthma (Dunnill 1960 bronchial mucosa of mild stable asthmatics, and some of the features seen in post-mortem examination were also present in this more benign form of asthma (Jeffery et al.1989 , Azzawi et al. 1990 ). The flurry of information that followed these seminal observations firmly established asthma as an inflammatory disease. The recent definition proposed by the Global Initiative for Asthma stated that asthma is a chronic inflammatory disease with many cells contributing to its pathogenesis (NHLBI/WHO 1995) . Eosinophils seem to play a key role in the establishment of bronchial inflammation in this condition, together with T lymphocytes that produce a set of cytokines typical of the Type 2 classification of Mossman and Coffman , Robinson et al. 1992 . The presence of activated eosinophils, displaying positivity for the cleaved form of the eosinophil cationic protein (ECP) was correlated with bronchial hyperresponsiveness to metacholine. Eosinophilia was identified in all types of asthma, such as atopic, non-atopic, and occupational (Saetta et al. 1992) . The possible role of eosinophils in asthma pathogenesis led to the development of diagnostic tools, such as the measurement of ECP in serum, bronchoalveolar lavage fluid or sputum of asthmatic patients, that can also be used as markers of disease progression or severity (Virchow et al. 1992) . However, the evidences for the actual role of eosinophils in many aspects of asthma remain circumstantial. A mechanistic approach to answer these standing questions demands the use of animal models of allergy.
CONTRIBUTION OF ANIMAL MODELS TO ESTAB-LISH CAUSALITY IN ALLERGIC INFLAMMATION
The booster injection of antigen in sensitized guinea pigs leads to bronchial eosinophilia -We have used an animal model to investigate the establishment of bronchial allergic inflammation. Sensitization of guinea pigs with ovalbumin, followed by a booster injection of antigen two weeks later induced a marked bronchial inflammation characterized by the presence of increased numbers of eosinophils and CD4+ T lymphocytes (Lapa e Silva et al. 1992 , 1993a . These events were temporally associated with enhanced bronchoconstriction to PAF and other agonists, and with release of secondary mediators in the effluent of the isolated perfused lungs (Pretolani et al. 1988) .
Antigen challenge in boosted animals further increases bronchial eosinophilia and results in extensive epithelial shedding -Sensitized and boosted animals were further challenged with ovalbumin after protection with anti-histaminic and 24 hr after the provocation a further increase in eosinophil numbers infiltrating the bronchial mucosa was seen, together with staining of extracellular granular material suggestive of eosinophil degranulation. Marked mucosal ulceration and epithelial shedding were noted in most animals of this group (Lapa e Silva et al. 1993b) .
Antigen challenge in boosted animals results in infiltration of the bronchial mucosa by dendritic cells -Animals provoked as above had their bronchial mucosa infiltrated 24 hr after challenge by cells with slender processes that stained very positive with a MHC Class II marker but failed to exhibit positivity for macrophages markers, thus suggesting that they were true dendritic cells . The presence of increased numbers of dendritic cells in the bronchial mucosa could indicate persistence of the immune response by continuing antigen-presentation to T cells.
Adhesion of VLA-4+ cells to vascular endothelium is a rapid event after antigen challenge and precedes bronchial inflammation -Guinea pigs sensitized by repeated ovalbumin inhalation were killed at 3, 6, 24, and 72 hr after the challenge. Sections were stained with the monoclonal antibody HP1/2 against the α4 chain of the integrin VLA-4. Positive cells adhering to the vascular endothelium of bronchial vessels were maximal at the first time point and remained high 6 hr after antigen challenge but failed to show differences at later time points (Lapa e Silva, unpublished observations).
Eosinophils are the first inflammatory cell type to increase in bronchial mucosa after challenge and remain high at all time points -Using the above model, we examined the nature of bronchial inflammation at the same time points. Eosinophil numbers were significantly higher than controls 3 hr after challenge and remained higher at all time points examined, whereas CD4+ cells were only higher than controls 24 hr after challenge (Lapa e Silva et al. 1995a).
USE OF IMMUNOLOGIC TOOLS TO INVESTIGATE CAUSALITY IN ALLERGIC INFLAMMATION
Antibody against α4 integrin prevents the development of eosinophilic bronchitis without affecting systemic eosinophilia -We used the monoclonal antibody HP1/2 as a tool to investigate the role of α4 integrins in the development of eosinophilic inflammation. Guinea pigs were sensitized by repeated inhalations of ovalbumin and provoked by the same route 14 days later and HP1/2 antibody was injected intravenously 1hr before and 4 hr after antigen challenge. The monoclonal antibody totally prevented eosinophilia in the bronchoalveolar lavage (BAL) fluid and markedly inhibited the rise of eosinophil peroxidase levels in the BAL fluid of treated animals, suggesting that neutralization of α4 integrin prevented not only the homing of eosinophils to the airways but also their degranulation . Treatment with HP1/ 2 entirely prevented mucosal infiltration by eosinophils and CD4+ T cells. Blood eosinophilia was selectively increased by the α4 integrin treatment, indicating that inhibition of eosinophil recruitment to the alveolar compartment may partially account for their accumulation in the circulation .
Antibody against α4 integrin blocks the development of bronchial hyperreactivity -The effects described above were also accompanied by a marked reduction in the bronchoconstrictor response to intravenous methacholine in animals treated with the anti-α4 integrin antibody, in comparison with those treated with the corresponding isotype ).
Antibody against eosinophil major basic protein (MBP) prevents the development of bronchial hyperreactivity without affecting bronchial inflammation -Guinea pigs were sensitized as above and purified rabbit anti-guinea pig MBP antibody was injected intranasally 1 hr before and 5 hr after ovalbumin inhalation. Both BAL eosinophilia and in-filtration of the bronchial mucosa by eosinophils were unaffected by antibody treatment, remaining similar to those seen in isotype-treated provoked animals. Bronchial hyperreactivity to acetylcholine, however, was markedly reduced in animals treated with the anti-MBP antibody, strongly suggesting a central role for this cationic protein in the development of altered functional states in allergic inflammation (Lefort et al. 1996) .
USE OF PHARMACOLOGIC TOOLS TO MODULATE ALLERGIC INFLAMMATION
Glucocorticosteroids but not nedocromil sodium decreases eosinophilic bronchitis -The effects of two standard anti-inflammatory drugs on the bronchial wall infiltration by eosinophils and other cell types were investigated using a guinea pig model. Animals were sensitized and boosted with ovalbumin and treated for five days after the booster injection of antigen with subcutaneous injection of either dexamethasone or nedocromil sodium. Bronchial infiltration by eosinophils and CD4+ cells was totally prevented by dexamethasone. Nedocromil sodium, however, failed to inhibit the eosinophilic bronchitis that accompanied the booster injection (Lapa e Silva et al. 1995b) .
FK506 markedly reduces bronchial inflammation -The novel immunosuppressive drug FK506 was used in an animal model of allergic inflammation to investigate its effects on the bronchial mucosa. Guinea pigs were sensitized and boosted with ovalbumin and treated for five days by subcutaneous injections of FK506 from the day of the booster injection. The drug totally prevented the development of bronchial infiltration by eosinophils and CD4+ T cells (Lapa e Silva et al. 1995b) .
FK506 blocks the development of bronchial hyperreactivity -We investigated the effects of FK506 on α4 integrin expression by inflammatory cells infiltrating the bronchi and on the emergence of bronchial hyperresponsiveness to acetylcholine. Guinea pigs received aerosol of avalbumin at days 0, 2, and were challenged at day 14. FK506 was administered 1hr before and 5 hr after challenge. Treatment by the immunosuppressant was accompanied by a marked decrease in numbers of CD4+ cells and eosinophils in the bronchial mucosa. FK506 also reversed the increase in α4 integrin positive cells adhering to the vascular endothelium and infiltrating the bronchial mucosa. We found preliminary evidence that the drug also prevented the development of bronchial hyperesponsiveness to acethylcholine, possibly through its action on cell recruitment to the bronchial mucosa. One possible mechanism for this action is down-regulation of α4 integrin expression on inflammatory cells (Lapa e Silva et al. 1996) .
CONCLUDING REMARKS
Data collected from studies with animal models of allergic inflammation establish a firm link between eosinophils and the development of pathologic changes in the bronchial mucosa, as well as with the accompanying functional state of hyperresponsiveness to agonists. Control of eosinophilia and of its causes are thus essential for a rational therapeutic approach in allergic inflammation.
